Physician profile
Murphy Barton
NPI 1306543665
$2,914.76
in general payments reported to CMS, 2019-2025
15 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $285 · 2024: $1,225 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,914.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,734.09 | 2023-2025 | |
| Axsome Therapeutics, INC. | $454.80 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $250.33 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.71 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $68.28 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $53.86 | 2023-2025 | |
| Ardelyx, INC. | $41.52 | 2025 | Ibsrela |
| Lilly USA, LLC | $39.37 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $35.22 | 2024 | Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $31.94 | 2024 | Uzedy |
| Novo Nordisk INC | $17.67 | 2023 | Rybelsus, Ozempic |
| Insulet Corporation | $17.07 | 2025 | Omnipod |
| Exact Sciences Corporation | $16.80 | 2025 | Cologuard Collection Kit |
| Corium, LLC | $15.81 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $15.29 | 2025 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murphy Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.